Journal of gastrointestinal oncology最新文献

{"title":"Efficacy observation of sequential TAS-102 following regorafenib as a later-line treatment in patients with metastatic colorectal cancer: a cohort study.","authors":"Chang Xu, Xiangyu Cheng, Changqing Liu, Jing Ren, Vishal G Shelat, Timothy Price, José María Sayagués, Yi Gai, Guangyu Wang, Yusheng Wang","doi":"10.21037/jgo-2025-47","DOIUrl":"10.21037/jgo-2025-47","url":null,"abstract":"<p><strong>Background: </strong>Metastatic colorectal cancer (mCRC) is associated with poor prognosis and limited options for later-line treatment. Regorafenib and TAS-102 have shown significant benefit and are recommended as later-line treatment for mCRC. This study aimed to investigate the progression-free survival (PFS) and overall survival (OS) of patients with mCRC treated with TAS-102 sequentially after regorafenib progression.</p><p><strong>Methods: </strong>This population-based cohort study retrospectively collected data of 30 patients with mCRC treated with TAS-102 sequentially after regorafenib at the Harbin Medical University Cancer Hospital and the Cancer Hospital Affiliated to Shanxi Medical University from January 1, 2020, to October 1, 2023. PFS and OS were considered to be the endpoints of this study. Kaplan-Meier analysis, log-rank test, and Cox proportional hazards regression analysis were used to analyze the OS, PFS, and risk factors.</p><p><strong>Results: </strong>Among the 30 patients included in the study, the median PFS (mPFS) for all patients was 3.83 months [95% confidence interval (CI): 3.09-5.59]. OS was divided into two categories: OS₁, the time from regorafenib initiation to death; OS₂, the time from TAS-102 initiation to death. The median OS₁ (mOS₁) was 18.7 months [95% CI: 16.3-not available (NA)], and the median OS₂ (mOS₂) was 16.1 months (95% CI: 8.08-NA). The mPFS was 3.65 and 3.83 months (P=0.68) in the regorafenib monotherapy group and combination therapy group, respectively, while the mOS₁ was unreached in the regorafenib monotherapy group and was 18.7 months in the regorafenib combination therapy group (P=0.64). Meanwhile, the mOS₁ was 17.5 and 20.7 months in the TAS-102 monotherapy group and TAS-102 combination therapy group, respectively (P=0.53). Univariate and multivariate Cox analyses revealed that curative surgery was an independent predictive factor for PFS.</p><p><strong>Conclusions: </strong>Our study demonstrated that the availability of sequential treatment options including regorafenib followed by TAS-102 prolongs the OS of patients compared to conventional monotherapy approaches. During the sequential treatment, regorafenib or TAS-102 combined with other therapeutic agents did not significantly differ from monotherapy, further investigation is required through large-scale trials.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 2","pages":"354-366"},"PeriodicalIF":2.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Four clamp-crush techniques in robotic hepatectomy (with video).","authors":"Koji Kikuchi, Hiroyuki Nitta, Akira Umemura, Hirokatsu Katagiri, Shoji Kanno, Daiki Takeda, Taro Ando, Satoshi Amano, Toma Kawashima, Taku Kimura, Hiroaki Shimada, Akihito Jo, Akira Sasaki","doi":"10.21037/jgo-2024-918","DOIUrl":"10.21037/jgo-2024-918","url":null,"abstract":"<p><p>Recently, reports of robotic hepatectomies have increased. In a laparoscopic hepatectomy, various energy devices are used for parenchymal transections, especially the clamp-crush method and the Cavitron Ultrasonic Surgical Aspirator (CUSA) system are popular; however, there is no CUSA that can be operated from the robot console. We believe that conventional clamp-crush method can be classified into four categories and have tried to verbalize them. We aim to explain the four types of clamp-crush techniques of robotic hepatectomy that we have performed and to assess their outcomes, safety, and feasibility. The data of patients who underwent robotic hepatectomy at Iwate Medical University Hospital between June 2022 and April 2024 were retrospectively reviewed. For comparison, 298 patients who underwent pure laparoscopic hepatectomy at Iwate Medical University Hospital between January 2014 and December 2020 were enrolled and analyzed. Our four clamp-crush techniques (Clamp, Peck, Open, Sweep) are demonstrated in the video clips provided with our study's electronic data. In the present study, 58 patients were included. In 27 cases (46.6%), a limited resection was performed; in 9 cases (15.5%), a subsegmentectomy; in 15 cases (25.9%), a sectionectomy; and in 7 cases (12.1%), a hemihepatectomy. The mean operative time was 205.9±90.5 min, and the mean intraoperative blood loss was 103.1±200.7 mL. There were no cases of conversion to a laparotomy. In comparison with laparoscopic hepatectomies, there were no significant differences in perioperative outcomes. The present findings indicate that robotic hepatectomies are safe and feasible in high-volume specialized centers with a team experienced in laparoscopic liver surgeries. It is possible to transition from laparoscopic hepatectomy to robotic hepatectomy without stress due to the fact that the same four clamp-crush techniques that are used in laparoscopic hepatectomy, which can be done in a robotic hepatectomy.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 2","pages":"778-785"},"PeriodicalIF":2.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078807/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic pancreatic acinar cell carcinoma with <i>BRCA2</i> gene alternation resected after modified FORFIRINOX therapy: a case report and literature review.","authors":"Shuhei Sugata, Atsushi Yamaguchi, Hiroki Kamada, Shigeaki Semba, Naohiro Kato, Yuji Teraoka, Takeshi Mizumoto, Yuzuru Tamaru, Tsuyoshi Hatakeyama, Hirotaka Kouno, Yoshiyuki Shibata, Sho Tazuma, Takeshi Sudo, Rie Yamamoto, Kazuya Kuraoka, Shigeto Yoshida, Shiro Oka","doi":"10.21037/jgo-24-845","DOIUrl":"10.21037/jgo-24-845","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic acinar cell carcinoma (PACC) is a rare subtype of pancreatic cancer, and its clinicopathological behavior is not fully understood because of its rarity. The excision of the tumor is the best treatment, but PACC patients often have distant metastasis at the time of first diagnosis and sometimes have relapse after surgery. Thus, appropriate anti-tumor agents need to be administered; however, there is still no standard chemotherapy regimen for PACC. We report a case of PACC in a patient with breast cancer susceptibility gene (<i>BRCA</i>)<i>2</i> gene alternation whose hepatic metastasis was shrunk by a treatment with a modified FORFIRINOX (mFFX) regimen. The patient also underwent conversion surgery after the mFFX treatment.</p><p><strong>Case description: </strong>A 67-year-old man was treated for breast cancer in 2016. In 2022, he experienced a continuous left back pain, and abdominal computed tomography (CT) revealed a 47-mm hypo-dense mass in the pancreatic tail and a 100-mm slightly enhanced mass in the liver at segment 8. He was diagnosed with PACC with liver metastasis by liver and pancreatic tumor biopsies. He was started on mFFX and, at the same time, we performed an analysis of the <i>BRCA</i> gene alternation with blood and genetic screening using a liver biopsy specimen. Later, the germline <i>BRCA2</i> gene alternation was identified, and mFFX was continued. He had considerable tumor shrinkage after 13 mFFX cycles and was then sent for surgery. An excised sample showed no tumor in the liver and a 900-µm residual tumor in the pancreatic tail. He had relapse in the liver at segment 6 at 12 months after surgery, which was then excised. He had a lymph node relapse at 3 months after the second surgery, and was receiving olaparib.</p><p><strong>Conclusions: </strong>mFFX might be prioritized as the first-line chemotherapy for PACC patients, and an analysis of the <i>BRCA</i> gene alternation needs to be conducted.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 2","pages":"726-737"},"PeriodicalIF":2.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective database analysis to understand treatment patterns and outcomes of intermediate and advanced hepatocellular carcinoma in Alberta, Canada (A-CAPTAIN study).","authors":"Carla P Amaro, Chloe A Lim, Philip Q Ding, Winson Y Cheung, Iqra Syed, YongJin Kim, Cal Shephard, Sharon Wang, Derek L Clouthier, Vincent C Tam","doi":"10.21037/jgo-24-692","DOIUrl":"10.21037/jgo-24-692","url":null,"abstract":"<p><strong>Background: </strong>With the emergence of new systemic therapies there has been a substantial change in treatment options for hepatocellular carcinoma (HCC). The aim of this study was to assess treatment patterns and outcomes in real-world Canadian HCC patients with intermediate and advanced stage disease who have received systemic treatments prior to 2021.</p><p><strong>Methods: </strong>All HCC patients with intermediate or advanced disease who received at least one dose of systemic therapy between January 1, 2008 to December 31, 2020 in the Canadian province of Alberta were included. Patient characteristics, treatment patterns, overall survival (OS), real-world progression-free survival (rwPFS), clinician-assessed response rates (RRs), and reasons for treatment discontinuation were retrospectively analyzed in all patients.</p><p><strong>Results: </strong>Of the 321 total patients included, 33 (10%) were intermediate and 288 (90%) were advanced stage. With respect to intermediate and advanced HCC patients, most were Eastern Cooperative Oncology Group (ECOG) 0-1 (94%, 85%, respectively) and Child-Pugh A (82% for both). For intermediate and advanced patients, RRs to first-line systemic therapy were 13% and 19%, median rwPFS was 7.4 and 4.2 months, and median OS was 13.5 and 10.9 months, respectively.</p><p><strong>Conclusions: </strong>This study characterized the systemic treatment patterns and outcomes of intermediate and advanced HCC patients treated prior to 2021 and can serve as a baseline for future comparison with HCC patients who predominantly receive first-line immunotherapy.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 2","pages":"650-659"},"PeriodicalIF":2.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarker-driven therapeutic strategies in advanced gastric cancer: a case series of curative responses.","authors":"Daniel Park, Lu Pu, Mengni Guo, Won Jin Jeon, Esther Chong, Kiwon Park, Yufei Liu, Gagandeep Brar, Chung-Tsen Hsueh, Dani Ran Castillo","doi":"10.21037/jgo-24-825","DOIUrl":"10.21037/jgo-24-825","url":null,"abstract":"<p><strong>Background: </strong>Treatment for initially unresectable/metastatic gastric cancer (UMGC) has traditionally been limited to palliative chemotherapy and supportive care. However, advances in biomarker-driven therapies, particularly dual blockade strategies targeting human epidermal growth factor receptor 2 (HER2) and immune checkpoints, offer the potential for curative outcomes, challenging this treatment paradigm.</p><p><strong>Case description: </strong>This case series presents four UMGC patients treated at Loma Linda University and City of Hope who achieved either pathologic complete response (pCR) or sustained responses following neoadjuvant chemotherapy incorporating dual blockade with anti-HER2 monoclonal antibodies and immune checkpoint inhibitors (ICIs). Initially deemed ineligible for curative resection due to disease extent, these patients demonstrated remarkable responses to biomarker-driven systemic therapy. Restaging imaging showed significant tumor regression, allowing for successful surgical resection. Histopathological findings confirmed treatment response, reinforcing the role of targeted therapies in downstaging disease and improving outcomes.</p><p><strong>Conclusions: </strong>These cases highlight the transformative impact of biomarker-driven therapy in advanced GC. The integration of programmed cell death ligand 1 (PD-L1) inhibitors and HER2-targeted agents alongside chemotherapy can enable curative-intent surgery in select patients who otherwise would have remained ineligible. These findings emphasize the importance of early biomarker testing to guide individualized treatment plans, ensuring optimal therapeutic benefit. Further studies are needed to refine patient selection criteria, optimize treatment sequencing, and establish standardized protocols integrating biomarker-driven approaches into the management of advanced GC.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 2","pages":"750-756"},"PeriodicalIF":2.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Camrelizumab in combination with chemotherapy and targeted therapy improves the prognosis in patients with advanced biliary tract cancer: a single-center retrospective clinical study.","authors":"Yizhuo Zhang, Xiaolong Liu, Guixing Jiang, Xinyu Dong, Hong Jae Chon, Giovanni Brandi, Daniel Neureiter, Defei Hong","doi":"10.21037/jgo-2025-184","DOIUrl":"10.21037/jgo-2025-184","url":null,"abstract":"<p><strong>Background: </strong>Biliary tract cancer (BTC) is an aggressive neoplasm with poor overall survival. Chemotherapy has improved the prognosis of BTC, but the outcomes still remain very unsatisfactory. Immune checkpoint inhibitor (ICI) therapy has shown promising efficacy in multiple solid tumors, including BTC. However, despite significant progress, the use of immunotherapy for the treatment of BTC is still in its early stages, and the evidence for its use is mixed, possibly due to inaccurate grouping based on the expression of programmed death ligand 1, a reliable candidate biomarker if carefully handled. Here, we reviewed the outcomes of camrelizumab, an Food and Drug Administration-approved anti-PD-1 ICI, combined with chemotherapy or targeted therapy in patients with advanced BTC.</p><p><strong>Methods: </strong>Patients with advanced BTC treated with camrelizumab in combination with chemotherapy or targeted therapy as the first-line therapy from September 2020 to September 2023 were included in this retrospective, non-randomized and single-center design study. Treatment efficacy and treatment-related adverse events were subjected to statistical analysis.</p><p><strong>Results: </strong>Fifteen patients were enrolled in this study. The mean age of the patients was 62 years (ranging from 25 to 75 years old), comprising 9 males and 6 females. The pathological diagnoses included 11 cases of intrahepatic cholangiocarcinoma, 1 case of extrahepatic cholangiocarcinoma, and 3 cases of gallbladder carcinoma. Among them, 5 cases diagnosed at stage IIa were deemed inoperable for surgery due to anticipated insufficient residual liver volume. Additionally, there were 5 cases classified as stage IIIb and 5 cases as stage IV. Seven patients achieved a partial response, and the study had an overall response rate of 46.7%. Seven patients had stable disease, with a disease control rate of 93.3%. At the cut-off date of September 30, 2023, the median follow-up time was 15.7 months (range, 1.7-33 months). The patients had a median progression-free survival time of 18 months (95% confidence interval: 12.4-not reached). Of the patients, nine (60.0%) were deemed eligible for surgery. Six patients (40%) developed grade III neutropenia, one (6.7%) developed grade IV neutropenia, and one (6.7%) developed grade III thrombocytopenia.</p><p><strong>Conclusions: </strong>The application of camrelizumab as neoadjuvant therapy in the treatment of patients with advanced BTC showed encouraging efficacy and safety.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 2","pages":"660-670"},"PeriodicalIF":2.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12078816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: MD2 blockage prevents the migration and invasion of hepatocellular carcinoma cells via inhibition of the EGFR signaling pathway.","authors":"","doi":"10.21037/jgo-2025b-02","DOIUrl":"10.21037/jgo-2025b-02","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.21037/jgo-21-362.].</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 1","pages":"333-335"},"PeriodicalIF":2.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic treatment for recurrence of hepatocellular carcinoma after liver transplantation: a case report.","authors":"Miaotian Deng, Chaobo Chen, Kun Wang, Binghua Li, Decai Yu","doi":"10.21037/jgo-24-480","DOIUrl":"10.21037/jgo-24-480","url":null,"abstract":"<p><strong>Background: </strong>Liver transplantation (LT) is considered the optimal treatment approach for patients with cirrhosis progressing to hepatocellular carcinoma (HCC). LT not only allows for complete removal of tumors from the liver but also potentially eliminates cirrhosis. However, recurrence of HCC after LT remains a significant issue, with recurrence rates ranging from 8% to 20%. The median time to recurrence is 14 months, and the median survival after recurrence is 12.2 months. We present the first case of long-term remission following hepatic arterial infusion chemotherapy (HAIC) combined with targeted therapy in a patient with multifocal recurrence and distant metastasis of HCC after LT.</p><p><strong>Case description: </strong>A 62-year-old male experienced recurrence of HCC after LT, with metastases to the sigmoid colon. Following multidisciplinary discussions, he received HAIC combined with small molecule targeted therapy. The liver tumor lesions and hemorrhagic foci remained stable, even tending to shrink, while tumor marker levels steadily declined. The patient did not experience any serious adverse events during treatment. Unfortunately, the patient developed acute enteritis with dysbiosis following a meal in March 2024, which led to rapid onset of septic shock, ultimately resulting in death.</p><p><strong>Conclusions: </strong>This case suggests that the combination of HAIC and targeted therapy may offer a promising approach for treating recurrent HCC after LT. These findings provide valuable insights for further exploration of treatment strategies for recurrent HCC post-LT and may contribute to advancing clinical research and practice for the benefit of patients.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 1","pages":"309-316"},"PeriodicalIF":2.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921418/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and validation of a nomogram model for predicting peritoneal metastasis in gastric cancer based on ferroptosis-relate genes and clinicopathological features.","authors":"Xiaotong Sun, Kaipeng Duan, Xiaochun Shen, Chao Dong, Yajing Zhou, Tao Chen, Weikang Li, Peiyuan Li, Pengbo Wang, Dongbao Li, Jin Zhou","doi":"10.21037/jgo-24-670","DOIUrl":"10.21037/jgo-24-670","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer peritoneal metastasis (GCPM) is a lethal condition. Current diagnostic methods for GCPM, such as imaging and serum tumor markers, lack specificity and sensitivity. Research suggests that utilizing gene signatures to predict GCPM shows significant predictive ability. Nonetheless, the predictability of GCPM using ferroptosis-related genes (FRGs) remains unknown. We aim to construct a nomogram based on FRGs for early diagnosis of GCPM.</p><p><strong>Methods: </strong>RNA sequencing and clinical data of patients with gastric cancer (GC) were downloaded from Gene Expression Omnibus (GEO) databases. GCPM was diagnosed through imaging, biopsy and cytology. A GCPM prediction model was developed based on six distinctively expressed FRGs, and the efficiency of the model was assessed through receiver operating characteristic (ROC) curves in both experimental and validation cohorts. Subsequently, 115 clinical samples were examined by immunohistochemistry (IHC) to validate the prediction model's accuracy.</p><p><strong>Results: </strong>Our analysis included 282 patients, among whom 54 had GCPM while 228 did not. Patients were randomly distributed into experimental and validation groups at a 3:2 ratio. Least absolute shrinkage and selection operator (LASSO) regression identified the coefficients of six FRGs, with a risk score calculated for every patient. Univariate and multivariate logistic analyses revealed that both risk score and pathological stage were significantly associated with GCPM. The area under the curve (AUC) values for the training and validating sets implied good predictability for GCPM (0.827 and 0.767, respectively). Combining the risk score with the tumor node metastasis (TNM) stage substantially improved predictability (AUCs were 0.916 and 0.848 respectively). Lastly, a nomogram incorporating the risk score and TNM stage was constructed, which shows good clinical utility through decision curve analysis (DCA). The IHC results from 115 clinical samples were consistent with these findings.</p><p><strong>Conclusions: </strong>A nomogram model based on FRGs and clinicopathological features was constructed, demonstrating impressive predictive value for GCPM. This enables timely and personalized therapeutic interventions, thereby benefiting gastric cancer patients.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 1","pages":"264-280"},"PeriodicalIF":2.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conversion resection of initially unresectable hepatocellular carcinoma associated with steatohepatitis through hepatic artery infusion chemotherapy-transarterial chemoembolization and systemic therapy: a case report.","authors":"Yi Zhou, Bin Guo, Honghao Zhou, Nan Wang, Zhenyu Xiao","doi":"10.21037/jgo-24-640","DOIUrl":"10.21037/jgo-24-640","url":null,"abstract":"<p><strong>Background: </strong>For advanced hepatocellular carcinoma (HCC), effective treatment options remain scarce. The risks of surgery and the likelihood of tumor residue restrict the use of liver resection. However, the combination of systemic therapy with locoregional treatments has recently demonstrated promising anti-tumor efficacy, offering new avenues for advanced HCC.</p><p><strong>Case description: </strong>We detail the case of a 61-year-old male who is free of viral hepatitis and alcohol consumption, but overweight with a body mass index (BMI) of 25.2 kg/m². A magnetic resonance imaging (MRI), ultrasound, and blood tests were conducted, leading to a diagnosis of HCC associated with steatohepatitis, along with a combined portal vein tumor thrombus. Following four rounds of hepatic artery infusion chemotherapy combined with transarterial chemoembolization (HAIC-TACE), 7 cycles of sintilimab treatment, and lenvatinib, there was marked tumor reduction and thrombus retraction to a peripheral branch. The patient subsequently underwent curative liver resection. Pathology revealed extensive necrosis within the tumor region and chronic hepatitis with steatosis in the adjacent liver tissue. No viable tumor tissue was identified. Now about 6 months after the operation, the patient is still in a tumor-free state.</p><p><strong>Conclusions: </strong>In this instance, we detail the effective transition of an HCC patient, with underlying steatohepatitis, to a treatment regimen that included HAIC-TACE along with sintilimab and lenvatinib. This approach yielded potent antitumor activity and was notably devoid of severe side effects. The outcome of this case expands the therapeutic horizon for managing HCC in the context of steatohepatitis.</p>","PeriodicalId":15841,"journal":{"name":"Journal of gastrointestinal oncology","volume":"16 1","pages":"301-308"},"PeriodicalIF":2.0,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143670108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}